Healthcare Utilization After Biologic Initiation for Chronic Rhinosinusitis.

Beau M Idler¹, Jananee Muralidharan², Gavin Hui², Noel F Ayoub³

¹Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

²Atropos Health, New York, NY, USA.

³Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA.

PubMed DOI

Abstract

BackgroundBiologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) broaden options beyond endoscopic sinus surgery (ESS) and conventional medications. However, the short-term impact of biologic therapy on healthcare utilization relative to ESS is unclear.ObjectiveTo compare 12-month healthcare utilization and costs after biologic initiation versus ESS.MethodsUsing the Atropos Healt…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.